Evidence map›Paper›PMID 35949144›Full record

ArticleEuropean heart journal. Acute cardiovascular care2022

Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock.

Mari Hongisto, Johan Lassus, Tuukka Tarvasmäki, Jordi Sans-Roselló, Heli Tolppanen, Anu Kataja, Toni Jäntti, Tuija Sabell, Marek Banaszewski, Jose Silva-Cardoso and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Acute cardiovascular care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Current and novel biomarkers in cardiogenic shock.European journal of heart failure · 2025
    Review
  2. Cardiogenic Shock: Focus on Non-Cardiac Biomarkers.Current heart failure reports · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 7 countries.

Mari HongistoEmergency Medicine, University of Helsinki, Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-9838-1248
Johan LassusCardiology, University of Helsinki and Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.
Tuukka TarvasmäkiCardiology, University of Helsinki and Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0003-3406-243X
Jordi Sans-RosellóCardiology Department, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Biomedical Research Institute IIB-Sant Pau, CIBER-CV, Spain.
Heli TolppanenCardiology, University of Helsinki and Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.
Anu KatajaEmergency Medicine, University of Helsinki, Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.
Toni JänttiCardiology, University of Helsinki and Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.
Tuija SabellCardiology, University of Helsinki and Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.
Marek BanaszewskiNational Institute of Cardiology, Warsaw, Poland.
Jose Silva-CardosoCINTESIS-Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, São João University Medical Center, Faculty of Medicine, University of Porto, Porto, Portugal.
John ParissisER and Heart Failure Unit, Attikon University Hospital, National and Kapodestrian University of Athens, Athens, Greece.
Raija JurkkoCardiology, University of Helsinki and Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland.
Jindrich SpinarSt. Ann university hospital and Medical faculty Masaryk University, Brno, Czech Republic.
Maaret CastrénEmergency Medicine, University of Helsinki, Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0001-7164-4733
Alexandre MebazaaUniversité de Paris, Inserm 942-MASCOT, Paris, France.
Josep MasipResearch Direction, Consorci Sanitari Integral, University of Barcelona, Barcelona, Spain.
Veli Pekka HarjolaEmergency Medicine, University of Helsinki, Department of Emergency Medicine and Services, Helsinki University Hospital, Helsinki, Finland.
CardShock Study Investigators and the GREAT Network
University of Helsinki · FIConsorci Sanitari Garraf · ESInserm · FRInstitute of Cardiology · PLMasaryk University · CZNational and Kapodistrian University of Athens · GRUniversidade do Porto · PTUniversitat Autònoma de Barcelona · ES

Funding

Aarne Koskelo FoundationDepartment of Emergency MedicineServices of Helsinki University Hospitalthe Finnish Cardiac Foundation
6 · The paper itself

Abstract

aimsSoluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker reflecting the level of immune activation. It has been shown to have prognostic value in acute coronary syndrome and heart failure as well as in critical illness. Considering the complex pathophysiology of cardiogenic shock (CS), we hypothesized suPAR might have prognostic properties in CS as well. The aim of this study was to assess the kinetics and prognostic utility of suPAR in CS. METHODS AND

resultsSuPAR levels were determined in serial plasma samples (0-96 h) from 161 CS patients in the prospective, observational, multicentre CardShock study. Kinetics of suPAR, its association with 90-day mortality, and additional value in risk-stratification were investigated. The median suPAR-level at baseline was 4.4 [interquartile range (IQR) 3.2-6.6)] ng/mL. SuPAR levels above median were associated with underlying comorbidities, biomarkers reflecting renal and cardiac dysfunction, and higher 90-day mortality (49% vs. 31%; P = 0.02). Serial measurements showed that survivors had significantly lower suPAR levels at all time points compared with nonsurvivors. For risk stratification, suPAR at 12 h (suPAR12h) with a cut-off of 4.4 ng/mL was strongly associated with mortality independently of established risk factors in CS: OR 5.6 (95% CI 2.0-15.5); P = 0.001) for death by 90 days. Adding suPAR12h > 4.4 ng/mL to the CardShock risk score improved discrimination identifying high-risk patients originally categorized in the intermediate-risk category.

conclusionSuPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients.

Indexed as

BiomarkerCardiogenic shockRisk stratificationsuPAR

Identifiers

PMID35949144
PMCPMC9629697
OpenAlexW4291001828

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.